4.7 Article

Extracellular vesicles engineered to bind albumin demonstrate extended circulation time and lymph node accumulation in mouse models

Journal

JOURNAL OF EXTRACELLULAR VESICLES
Volume 11, Issue 7, Pages -

Publisher

WILEY
DOI: 10.1002/jev2.12248

Keywords

albumin binding domains; circulation time; extracellular vesicles; lymph node accumulation; tetraspanins

Categories

Funding

  1. Swedish Foundation of Strategic research
  2. ERC-CoG
  3. Swedish Research Council [2020-01322]
  4. Center for Medical Innovation [FoUI-963452]
  5. Evox Therapeutics
  6. Swedish Research Council [2020-01322] Funding Source: Swedish Research Council

Ask authors/readers for more resources

This study explores an engineering strategy to prolong the circulation time of extracellular vesicles (EVs) by decorating the surface with albumin. The engineered EVs demonstrate strong binding capacity and significantly increased circulation time after injection in mice. Furthermore, they accumulate in lymph nodes and solid tumors, which can be utilized for immunomodulation, cancer therapy, and immunotherapy.
Extracellular vesicles (EVs) have shown promise as potential therapeutics for the treatment of various diseases. However, their rapid clearance after administration could be a limitation in certain therapeutic settings. To solve this, an engineering strategy is employed to decorate albumin onto the surface of the EVs through surface display of albumin binding domains (ABDs). ABDs were either included in the extracellular loops of select EV-enriched tetraspanins (CD63, CD9 and CD81) or directly fused to the extracellular terminal of single transmembrane EV-sorting domains, such as Lamp2B. These engineered EVs exert robust binding capacity to human serum albumins (HSA) in vitro and mouse serum albumins (MSA) after injection in mice. By binding to MSA, circulating time of EVs dramatically increases after different routes of injection in different strains of mice. Moreover, these engineered EVs show considerable lymph node (LN) and solid tumour accumulation, which can be utilized when using EVs for immunomodulation, cancer- and/or immunotherapy. The increased circulation time of EVs may also be important when combined with tissue-specific targeting ligands and could provide significant benefit for their therapeutic use in a variety of disease indications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available